CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent

J Wang, BA Tannous, MC Poznansky, H Chen - Pharmacological research, 2020 - Elsevier
Abstract AMD3100 (plerixafor), a CXCR4 antagonist, has opened a variety of avenues for
potential therapeutic approaches in different refractory diseases. The CXCL12/CXCR4 axis …

Hsp70 in cancer: A double agent in the battle between survival and death

MA Vostakolaei, L Hatami‐Baroogh… - Journal of cellular …, 2021 - Wiley Online Library
The heat shock protein (Hsps) superfamily, also known as molecular chaperones, are highly
conserved and present in all living organisms and play vital roles in protein fate. The …

Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells

L Qin, Y Lai, R Zhao, X Wei, J Weng, P Lai, B Li… - Journal of hematology & …, 2017 - Springer
Background Multiple iterations of chimeric antigen receptors (CARs) have been developed,
mainly focusing on intracellular signaling modules. However, the effect of non-signaling …

Immunotherapeutic approaches to ovarian cancer treatment

C Chester, O Dorigo, JS Berek, H Kohrt - Journal for immunotherapy of …, 2015 - Springer
Despite advances in combinatorial chemotherapy regimens and the advent of
intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer …

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies

A Bononi, A Napolitano, HI Pass, H Yang… - Expert review of …, 2015 - Taylor & Francis
Malignant mesothelioma is an aggressive cancer whose pathogenesis is causally linked to
occupational exposure to asbestos. Familial clusters of mesotheliomas have been observed …

Cancer vaccines in ovarian cancer: how can we improve?

S Martin Lluesma, A Wolfer, A Harari, LE Kandalaft - Biomedicines, 2016 - mdpi.com
Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death.
Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and …

Immunogenicity of a xenogeneic multi-epitope HER2+ breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205

A Gül, M Döşkaya, H Can, M Karakavuk, M Anıl-İnevi… - Vaccine, 2022 - Elsevier
Breast cancer was ranked first in global cancer incidence in 2020, and HER2
overexpression in breast cancer accounts for 20–30% of breast cancer patients. Current …

AMD3100 augments the efficacy of mesothelin-targeted, immune-activating VIC-008 in mesothelioma by modulating intratumoral immunosuppression

B Li, Y Zeng, PM Reeves, C Ran, Q Liu, X Qu… - Cancer immunology …, 2018 - AACR
Abstract AMD3100 (plerixafor), a CXCR4 antagonist, has been demonstrated to suppress
tumor growth and modulate intratumoral T-cell trafficking. However, the effect of AMD3100 …

[HTML][HTML] Diversity of extracellular HSP70 in cancer: advancing from a molecular biomarker to a novel therapeutic target

B Hu, G Liu, K Zhao, G Zhang - Frontiers in Oncology, 2024 - ncbi.nlm.nih.gov
Abstract Heat shock protein 70 (HSP70) is a highly conserved protein functioning as a
“molecular chaperone”, which is integral to protein folding and maturation. In addition to its …

Hitting the bull's-eye: mesothelin's role as a biomarker and therapeutic target for malignant pleural mesothelioma

D Yeo, L Castelletti, N van Zandwijk, JEJ Rasko - Cancers, 2021 - mdpi.com
Simple Summary Mesothelioma is a deadly disease with a dismal prognosis. Since its
discovery, mesothelin, a cell surface protein, has been a promising biomarker and …